SCHEMBL12430905

SCHEMBL12430905

COc1ccc(-c2cc(Nc3cc(C)[nH]n3)nc(Oc3ccc(NC(C)=O)cc3)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ AURKB Q96GD4 5/20 0.57
▸ AURKA O14965 5/20 0.57
▸ EGFR P00533 4/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ ADORA3 P0DMS8 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ PIK3C3 Q8NEB9 2/20 0.48
▸ TNIK Q9UKE5 1/20 0.48
▸ SLC2A1 P11166 1/20 0.48
▸ GSK3B P49841 1/20 0.47
▸ ADORA2A P29274 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12430887 0.91 AURKA (0.68) AURKBAURKAEGFRSMN1; SMN2ALDH1A1
SCHEMBL12510643 0.88 AURKB (0.58) AURKBAURKAEGFRSMN1; SMN2ALDH1A1
SCHEMBL12430901 0.87 AURKA (0.57) AURKBAURKAEGFRSMN1; SMN2ALDH1A1
SCHEMBL12430818 0.84 AURKB (0.80) AURKBAURKAGSK3B
SCHEMBL12430896 0.81 AURKB (0.69) AURKBAURKAEGFRALDH1A1PIK3C3
SCHEMBL12430898 0.80 AURKB (0.54) AURKBAURKAEGFRADORA3TNIK
SCHEMBL12430913 0.80 AURKB (0.58) AURKBAURKAEGFRPIK3C3GSK3B
SCHEMBL3965081 0.80 AURKA (0.51) AURKBAURKAEGFRSMN1; SMN2ALDH1A1
SCHEMBL3963992 0.80 AURKA (0.51) AURKBAURKAEGFRTNIKSLC2A1
SCHEMBL3967694 0.78 AURKA (0.51) AURKBAURKAEGFRSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 — — US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 — — US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 — — US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 — — US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 — — US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 — — US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 — — US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA AURKB 7/4885AURKA 3/4885EGFR 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback